GCLLSG 2016 | Prognostic markers for CLL – how do they help determine who gets which treatment?
Petra Langerbeins, MD of University of Cologne, Cologne, Germany discusses prognostic markers for chronic lymphocytic leukemia (CLL). Dr Langerbeins explains that every group and institute has their own prognostic markers that they use for treatment decisions and advising patients. For the CLL12 trial (NCT02863718), they identified eight prognostic markers and they use them to decide when to start treatment. She also warns to be cautious as some patients may have unfavorable prognostic markers but that doesn’t mean that their disease will always progress.
Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
Get great new content delivered to your inboxSign up